James M. Luther

4.7k total citations · 1 hit paper
71 papers, 2.7k citations indexed

About

James M. Luther is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, James M. Luther has authored 71 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Endocrinology, Diabetes and Metabolism, 19 papers in Surgery and 18 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in James M. Luther's work include Hormonal Regulation and Hypertension (32 papers), Eicosanoids and Hypertension Pharmacology (11 papers) and Cardiovascular, Neuropeptides, and Oxidative Stress Research (9 papers). James M. Luther is often cited by papers focused on Hormonal Regulation and Hypertension (32 papers), Eicosanoids and Hypertension Pharmacology (11 papers) and Cardiovascular, Neuropeptides, and Oxidative Stress Research (9 papers). James M. Luther collaborates with scholars based in United States, Australia and France. James M. Luther's co-authors include Nancy J. Brown, Kevin L. Schey, Chang Yu, Kristie L. Rose, David L. Hachey, Agnes B. Fogo, Hui Nian, Zhen Wang, Salisha Hill and Douglas E. Vaughan and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

James M. Luther

69 papers receiving 2.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

2025 23 citations James M. Luther et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James M. Luther United States	31	1.2k	757	595	556	259	71	2.7k
Mark E. Cooper Australia	34	1.0k 0.9×	1.4k 1.8×	443 0.7×	861 1.5×	253 1.0×	67	4.6k
Wenquan Niu China	32	605 0.5×	743 1.0×	488 0.8×	605 1.1×	254 1.0×	191	3.1k
Christos Tikellis Australia	25	1.2k 1.0×	1.1k 1.4×	531 0.9×	1.3k 2.3×	455 1.8×	30	3.7k
Bruno Fabris Italy	37	1.9k 1.6×	991 1.3×	1.3k 2.2×	1.3k 2.4×	258 1.0×	155	4.1k
Michael Feher United Kingdom	25	1.1k 0.9×	543 0.7×	707 1.2×	410 0.7×	148 0.6×	137	2.5k
Chris Tikellis Australia	27	622 0.5×	763 1.0×	287 0.5×	749 1.3×	243 0.9×	41	2.5k
Andreas Gardemann Germany	32	488 0.4×	656 0.9×	504 0.8×	737 1.3×	213 0.8×	72	2.6k
Laurence Duvillard France	34	1.5k 1.3×	555 0.7×	911 1.5×	719 1.3×	127 0.5×	128	3.3k
Masayoshi Soma Japan	34	1.3k 1.1×	1.4k 1.8×	596 1.0×	1.2k 2.2×	346 1.3×	256	4.6k
Ulrich Julius Germany	28	1.5k 1.3×	548 0.7×	1.5k 2.4×	735 1.3×	185 0.7×	173	3.6k

Countries citing papers authored by James M. Luther

Since Specialization

Citations

This map shows the geographic impact of James M. Luther's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James M. Luther with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James M. Luther more than expected).

Fields of papers citing papers by James M. Luther

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James M. Luther. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James M. Luther. The network helps show where James M. Luther may publish in the future.

Co-authorship network of co-authors of James M. Luther

This figure shows the co-authorship network connecting the top 25 collaborators of James M. Luther. A scholar is included among the top collaborators of James M. Luther based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James M. Luther. James M. Luther is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bandulik, Sascha, Chandan Kumar‐Sinha, Aaron M. Udager, et al.. (2025). Somatic Mutations in MCOLN3 Are Associated With Aldosterone-Producing Adenomas. Hypertension. 82(10). 1778–1788. 2 indexed citations

Mashayekhi, Mona, Hui Nian, Jessica K. Devin, et al.. (2025). RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide. Journal of Endocrinology. 267(1).

Ghoshal, Kakali, James M. Luther, Suman Pakala, et al.. (2024). Epoxygenase Cyp2c44 Regulates Hepatic Lipid Metabolism and Insulin Signaling by Controlling FATP2 Localization and Activation of the DAG/PKCδ Axis. Diabetes. 73(8). 1229–1243. 4 indexed citations

Heydarpour, Mahyar, et al.. (2022). Salt Sensitivity of Blood Pressure and Aldosterone: Interaction Between the Lysine-specific Demethylase 1 Gene, Sex, and Age. The Journal of Clinical Endocrinology & Metabolism. 107(5). 1294–1302. 10 indexed citations

Brown, Jenifer M., et al.. (2022). Recalibrating Interpretations of Aldosterone Assays Across the Physiologic Range: Immunoassay and Liquid Chromatography–Tandem Mass Spectrometry Measurements Under Multiple Controlled Conditions. Journal of the Endocrine Society. 6(6). bvac049–bvac049. 24 indexed citations

Bhalla, Vivek, Stephen C. Textor, Joshua A. Beckman, et al.. (2022). Revascularization for Renovascular Disease: A Scientific Statement From the American Heart Association. Hypertension. 79(8). e128–e143. 25 indexed citations

Mashayekhi, Mona, Celestine N. Wanjalla, Kakali Ghoshal, et al.. (2021). The soluble epoxide hydrolase inhibitor GSK2256294 decreases the proportion of adipose pro-inflammatory T cells. Prostaglandins & Other Lipid Mediators. 158. 106604–106604. 5 indexed citations

Sparks, Matthew A., Andrew M. South, Paul A. Welling, et al.. (2020). Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19. Clinical Journal of the American Society of Nephrology. 15(5). 714–716. 57 indexed citations

Nian, Hui, et al.. (2020). Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data. BMJ Open. 10(5). e033100–e033100. 5 indexed citations

10.

Luther, James M. & Agnes B. Fogo. (2019). Under pressure—how to assess blood pressure in rodents: tail-cuff?. Kidney International. 96(1). 34–36. 5 indexed citations

11.

Gangadhariah, Mahesha, Shaojun Mei, Shouzuo Wei, et al.. (2018). The Cytochrome P450 Slow Metabolizers CYP2C9*2 and CYP2C9*3 Directly Regulate Tumorigenesis via Reduced Epoxyeicosatrienoic Acid Production. Cancer Research. 78(17). 4865–4877. 27 indexed citations

12.

Luther, James M.. (2015). Aldosterone in vascular and metabolic dysfunction. Current Opinion in Nephrology & Hypertension. 25(1). 16–21. 20 indexed citations

13.

Luther, James M., Loretta M. Byrne, Chang Yu, Thomas J. Wang, & Nancy J. Brown. (2014). Dietary Sodium Restriction Decreases Insulin Secretion Without Affecting Insulin Sensitivity in Humans. The Journal of Clinical Endocrinology & Metabolism. 99(10). E1895–E1902. 24 indexed citations

14.

Gangadhariah, Mahesha, James M. Luther, Víctor García, et al.. (2014). Hypertension Is a Major Contributor to 20-Hydroxyeicosatetraenoic Acid–Mediated Kidney Injury in Diabetic Nephropathy. Journal of the American Society of Nephrology. 26(3). 597–610. 43 indexed citations

15.

Nian, Hui, et al.. (2013). Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension. Journal of Hypertension. 31(4). 820–829. 30 indexed citations

16.

Chamarthi, Bindu, G. H. Williams, Vincent Ricchiuti, et al.. (2011). Inflammation and Hypertension: The Interplay of Interleukin-6, Dietary Sodium, and the Renin-Angiotensin System in Humans. American Journal of Hypertension. 24(10). 1143–1148. 118 indexed citations

17.

Lea, William, et al.. (2009). Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney International. 75(9). 936–944. 93 indexed citations

18.

Marney, Annis, Ji Ma, James M. Luther, T. Alp İkizler, & Nancy J. Brown. (2009). Endogenous Bradykinin Contributes to Increased Plasminogen Activator Inhibitor 1 Antigen following Hemodialysis. Journal of the American Society of Nephrology. 20(10). 2246–2252. 15 indexed citations

19.

Guilder, Gary P. Van, Mias Pretorius, James M. Luther, et al.. (2008). Bradykinin Type 2 Receptor BE1 Genotype Influences Bradykinin-Dependent Vasodilation During Angiotensin-Converting Enzyme Inhibition. Hypertension. 51(2). 454–459. 36 indexed citations

20.

Luther, James M., James V. Gainer, Laine J. Murphey, et al.. (2006). Angiotensin II Induces Interleukin-6 in Humans Through a Mineralocorticoid Receptor–Dependent Mechanism. Hypertension. 48(6). 1050–1057. 125 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact